Trial record 1 of 3 for:    perifosine colorectal
Previous Study | Return to List | Next Study

Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer (X-PECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01097018
Recruitment Status : Completed
First Posted : April 1, 2010
Last Update Posted : July 2, 2013
Information provided by (Responsible Party):
AEterna Zentaris

Brief Summary:
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Capecitabine Drug: Perifosine Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 468 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Study Start Date : April 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Perifosine + Capecitabine
Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
Drug: Capecitabine
1000 mg/m2 BID/ Days 1-14

Drug: Perifosine
50 mg daily x 21 days

Placebo Comparator: Placebo + Capecitabine
Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
Drug: Capecitabine
1000 mg/m2 BID/ Days 1-14

Drug: Placebo
1 pill daily x 21 days

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Monthly ]

Secondary Outcome Measures :
  1. Progression-free Survival [ Time Frame: Every 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have failed available therapy for the treatment of advanced colorectal cancer, including fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab and for K-ras wild-type (WT) patients, anti-EGFR antibody (cetuximab or panitumumab) containing therapies.
  • For oxaliplatin-based therapy, failure of therapy will also include patients who had oxaliplatin discontinued secondary to toxicity.
  • No prior exposure to capecitabine in the metastatic colorectal cancer setting, except limited-course radiosensitizing capecitabine
  • Patients must have at least one measurable lesion by RECIST criteria

Exclusion Criteria:

  • Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe reaction to 5-FU

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01097018

  Hide Study Locations
United States, California
Alhambra, California, United States, 91801
Bakersfield, California, United States, 93309
La Verne, California, United States, 91750
Long Beach, California, United States, 90813
Los Angeles, California, United States, 90095
Northridge, California, United States, 91325
Redondo Beach, California, United States, 90277
Santa Barbara, California, United States, 93105
Santa Maria, California, United States, 93454
United States, Colorado
Denver, Colorado, United States, 80218
Grand Junction, Colorado, United States, 81501
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520
Stamford, Connecticut, United States, 06902
Waterbury, Connecticut, United States, 06708
United States, Florida
Fort Myers, Florida, United States, 33916
Hollywood, Florida, United States, 33021
Pembroke Pines, Florida, United States, 33028
United States, Georgia
Athens, Georgia, United States, 30607
Atlanta, Georgia, United States, 30341
Lawrenceville, Georgia, United States, 30046
Marietta, Georgia, United States, 30060
Roswell, Georgia, United States, 30076
United States, Illinois
Harvey, Illinois, United States, 60467
Park Ridge, Illinois, United States, 60068
United States, Indiana
South Bend, Indiana, United States, 44601
Terre Haute, Indiana, United States, 47802
United States, Maryland
Baltimore, Maryland, United States, 21287
Bethesda, Maryland, United States, 20817
United States, Michigan
Lansing, Michigan, United States, 48912
United States, Mississippi
Jackson, Mississippi, United States, 39202
Tupelo, Mississippi, United States, 38801
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, Nebraska
Lincoln, Nebraska, United States, 68510
United States, Nevada
Henderson, Nevada, United States, 89052
Las Vegas, Nevada, United States, 89169
United States, New Jersey
Morristown, New Jersey, United States, 07960
United States, New Mexico
Albuquerque, New Mexico, United States, 87106
Albuquerque, New Mexico, United States, 87110
United States, New York
Armonk, New York, United States, 10504
Great Neck, New York, United States, 11042
New Hyde Park, New York, United States, 11040
New York City, New York, United States, 10016
United States, North Carolina
Charlotte, North Carolina, United States, 28204
United States, North Dakota
Bismark, North Dakota, United States, 58504
Fargo, North Dakota, United States, 58122
United States, Ohio
Cincinnati, Ohio, United States, 45242
Columbus, Ohio, United States, 43210
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, South Carolina
Columbia, South Carolina, United States, 29210
United States, Tennessee
Chattanooga, Tennessee, United States, 37404
Memphis, Tennessee, United States, 38120
TN Oncology
Nashville, Tennessee, United States, 37203
United States, Texas
Abilene, Texas, United States, 79606
Austin, Texas, United States, 78731
Beaumont, Texas, United States, 77702
Dallas, Texas, United States, 75230
Dallas, Texas, United States, 75231
Dallas, Texas, United States, 75246
Fort Worth, Texas, United States, 76104
Houston, Texas, United States, 77030
Midland, Texas, United States, 79701
Tyler, Texas, United States, 75702
United States, Virginia
Richmond, Virginia, United States, 23230
United States, Washington
Seattle, Washington, United States, 98104
Spokane, Washington, United States, 99208
Sponsors and Collaborators
AEterna Zentaris
Principal Investigator: Johanna Bendell, MD SCRI Development Innovations, LLC

Additional Information:
Publications of Results:
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). Abstract Number:LBA3501

Responsible Party: AEterna Zentaris Identifier: NCT01097018     History of Changes
Other Study ID Numbers: Protocol 343
First Posted: April 1, 2010    Key Record Dates
Last Update Posted: July 2, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents